Walker's Research Business Information
A publisher of Business Information since 1983  
Search Business Search Executive   Advanced Search
 |  Sign In  |  Hints
Company Name Amylin Pharmaceuticals Inc. Ticker Symbol AMLN

 Address 9360 Towne Ctr. Dr.
San Diego, CA 92121
United States
Email ir@amylin.com Phone 1-858-552-2200
Website www.amylin.com Fax 1-858-552-2212

Business Information

The group's principal activity is to discover, develop and markets potential drug candidates for the treatment of diabetes and other metabolic disorders. It has exclusive rights to two drug candidates, which are in late-stage development, for the treatment of diabetes, symlin(TM) (pramlintide acetate) and ac2993 (synthetic exendin-4). Symlin(TM) is a synthetic analog of the human hormone, amylin for the treatment of the people with diabetes who use insulin. Ac2993, a code name for synthetic exendin-4, is for the treatment of type 2 diabetes. The group also has a third drug candidate ac3056, which is in early stage clinical trials. It is used in the treatment of metabolic disorders relating to cardiovascular disease.

Executive Information
Name Title Email
Jeffrey FriedmanChmn. - Scientific Advisory Board N/A
Joseph CookChmn. N/A
Robert SherwinChmn. - North American Advisory Board N/A
Daniel BradburyDir., CEO, Pres. N/A
Lloyd RowlandVP - Governance, Compliance, Corp. Sec. N/A

Financial Information  ( All figures in $ '000 )
Year Sales Net Income
2006 510,875(218,856)
2005 140,474(206,832)
2004 34,268(157,157)

Click for more Executives

            Home  |  About Us  |  Product Information   |  Subscription  |  List Builder   |  Executive List   |  Email Lists   |  Contact Us  |  Site Map  |  Browse Directory   

© 2009, Walkers's Research - A publisher of Business Information since 1983, All Rights Reserved.